Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Intra-ophthalmic artery chemotherapy triggers vascular toxicity through endothelial cell inflammation and leukostasis.

Steinle JJ, Zhang Q, Thompson KE, Toutounchian J, Yates CR, Soderland C, Wang F, Stewart CF, Haik BG, Williams JS, Jackson JS, Mandrell TD, Johnson D, Wilson MW.

Invest Ophthalmol Vis Sci. 2012 Apr 30;53(4):2439-45. doi: 10.1167/iovs.12-9466.

2.

Superselective intraophthalmic artery chemotherapy in a nonhuman primate model: histopathologic findings.

Tse BC, Steinle JJ, Johnson D, Haik BG, Wilson MW.

JAMA Ophthalmol. 2013 Jul;131(7):903-11. doi: 10.1001/jamaophthalmol.2013.2065.

3.

Real-time ophthalmoscopic findings of superselective intraophthalmic artery chemotherapy in a nonhuman primate model.

Wilson MW, Jackson JS, Phillips BX, Buchanan J, Frase S, Wang F, Steinle JJ, Stewart CF, Mandrell TD, Haik BG, Williams JS.

Arch Ophthalmol. 2011 Nov;129(11):1458-65. doi: 10.1001/archophthalmol.2011.330.

4.

A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results.

Abramson DH, Dunkel IJ, Brodie SE, Kim JW, Gobin YP.

Ophthalmology. 2008 Aug;115(8):1398-404, 1404.e1. doi: 10.1016/j.ophtha.2007.12.014. Epub 2008 Mar 14.

PMID:
18342944
5.

Superselective ophthalmic artery chemotherapy as primary treatment for retinoblastoma (chemosurgery).

Abramson DH, Dunkel IJ, Brodie SE, Marr B, Gobin YP.

Ophthalmology. 2010 Aug;117(8):1623-9. doi: 10.1016/j.ophtha.2009.12.030. Epub 2010 Apr 9.

PMID:
20381868
6.

Toxic effects of melphalan, topotecan and carboplatin on retinal pigment epithelial cells.

Süsskind D, Hagemann U, Schrader M, Januschowski K, Schnichels S, Aisenbrey S.

Acta Ophthalmol. 2016 Aug;94(5):471-8. doi: 10.1111/aos.12990. Epub 2016 Feb 19.

7.

Efficacy and complications of super-selective intra-ophthalmic artery melphalan for the treatment of refractory retinoblastoma.

Muen WJ, Kingston JE, Robertson F, Brew S, Sagoo MS, Reddy MA.

Ophthalmology. 2012 Mar;119(3):611-6. doi: 10.1016/j.ophtha.2011.08.045. Epub 2011 Dec 22.

PMID:
22197434
8.

Retinal vascular precipitates during administration of melphalan into the ophthalmic artery.

Superstein R, Lederer D, Dubois J, Hamel P, Carret AS, Callejo S.

JAMA Ophthalmol. 2013 Jul;131(7):963-5. doi: 10.1001/jamaophthalmol.2013.1469. No abstract available.

PMID:
23846208
9.

In search of underlying mechanisms and potential drugs of melphalan-induced vascular toxicity through retinal endothelial cells using bioinformatics approach.

Yang Y, Xing Y, Liang C, Hu L, Xu F, Mei Q.

Tumour Biol. 2016 May;37(5):6709-18. doi: 10.1007/s13277-015-4444-5. Epub 2015 Dec 9.

PMID:
26662105
10.

Selective Ophthalmic Artery Infusion Chemotherapy for Advanced Intraocular Retinoblastoma: CCHMC Early Experience.

Michaels ST, Abruzzo TA, Augsburger JJ, Corrêa ZM, Lane A, Geller JI.

J Pediatr Hematol Oncol. 2016 Jan;38(1):65-9. doi: 10.1097/MPH.0000000000000471.

PMID:
26583615
11.

Selective ophthalmic arterial infusion of chemotherapeutic drugs for recurrent retinoblastoma.

Trinavarat A, Chiewvit P, Buaboonnam J, Sanpakit K, Atchaneeyasakul LO.

J Pediatr Hematol Oncol. 2012 Aug;34(6):e218-21. doi: 10.1097/MPH.0b013e318253f09e.

PMID:
22584782
12.

Selective ophthalmic artery infusion of chemotherapy for advanced intraocular retinoblastoma: initial experience with 17 tumors.

Peterson EC, Elhammady MS, Quintero-Wolfe S, Murray TG, Aziz-Sultan MA.

J Neurosurg. 2011 Jun;114(6):1603-8. doi: 10.3171/2011.1.JNS10466. Epub 2011 Feb 4.

PMID:
21294621
13.

Fluorescein angiographic findings after intra-arterial chemotherapy for retinoblastoma.

Bianciotto C, Shields CL, Iturralde JC, Sarici A, Jabbour P, Shields JA.

Ophthalmology. 2012 Apr;119(4):843-9. doi: 10.1016/j.ophtha.2011.09.040. Epub 2011 Dec 2.

PMID:
22137042
14.

Occurrence of sectoral choroidal occlusive vasculopathy and retinal arteriolar embolization after superselective ophthalmic artery chemotherapy for advanced intraocular retinoblastoma.

Munier FL, Beck-Popovic M, Balmer A, Gaillard MC, Bovey E, Binaghi S.

Retina. 2011 Mar;31(3):566-73. doi: 10.1097/IAE.0b013e318203c101.

PMID:
21273941
15.

Selective ophthalmic intra-arterial melphalan therapy for advanced retinoblastoma: implementation and outcomes of a new chemotherapy protocol.

Valero García S, López Briz E, Escobar Cava P, Balaguer J, Pelufo A, Megías JE, Poveda Andrés JL.

J Oncol Pharm Pract. 2013 Jun;19(2):159-64. doi: 10.1177/1078155212457964. Epub 2012 Sep 25.

PMID:
23014898
16.

Electroretinogram monitoring of dose-dependent toxicity after ophthalmic artery chemosurgery in retinoblastoma eyes: six year review.

Francis JH, Abramson DH, Gobin YP, Marr BP, Dunkel IJ, Riedel ER, Brodie SE.

PLoS One. 2014 Jan 20;9(1):e84247. doi: 10.1371/journal.pone.0084247. eCollection 2014.

17.

Pearls and pitfalls of intraarterial chemotherapy for retinoblastoma.

Jabbour P, Chalouhi N, Tjoumakaris S, Gonzalez LF, Dumont AS, Chitale R, Rosenwasser R, Bianciotto CG, Shields C.

J Neurosurg Pediatr. 2012 Sep;10(3):175-81. doi: 10.3171/2012.5.PEDS1277. Epub 2012 Jul 13. Review.

PMID:
22793160
18.

Verification of supraselective drug delivery for retinoblastoma using intra-arterial gadolinium.

Materin MA, Kuzmik GA, Jubinsky PT, Minja FJ, Asnes JD, Bulsara KR.

BMJ Case Rep. 2012 Nov 15;2012. pii: bcr2012010508. doi: 10.1136/bcr-2012-010508.

19.

Local and systemic toxicity of intravitreal melphalan for vitreous seeding in retinoblastoma: a preclinical and clinical study.

Francis JH, Schaiquevich P, Buitrago E, Del Sole MJ, Zapata G, Croxatto JO, Marr BP, Brodie SE, Berra A, Chantada GL, Abramson DH.

Ophthalmology. 2014 Sep;121(9):1810-7. doi: 10.1016/j.ophtha.2014.03.028. Epub 2014 May 10.

PMID:
24819859
20.

Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis.

Suzuki S, Yamane T, Mohri M, Kaneko A.

Ophthalmology. 2011 Oct;118(10):2081-7. doi: 10.1016/j.ophtha.2011.03.013. Epub 2011 Jun 29.

PMID:
21715012

Supplemental Content

Support Center